Bharat Biotech International Ltd.

Bharat Biotech's Oral Cholera Vaccine 'Hillchol' Successfully Completes Phase III Trials

4 days ago

• Bharat Biotech's oral cholera vaccine Hillchol has demonstrated non-inferiority against both Ogawa and Inaba serotypes in Phase III clinical trials involving 1,800 participants across India. • The successful trial results position Hillchol as a potential solution to the global oral cholera vaccine shortage, with Bharat Biotech's facilities capable of producing up to 200 million doses annually. • Cholera affects approximately 2.86 million people and causes 95,000 deaths annually worldwide, highlighting the significant public health impact of this vaccine development.

Bharat Biotech Invests $75 Million in India's First Integrated Cell and Gene Therapy Facility

2 months ago

• Bharat Biotech has launched India's first integrated Cell and Gene Therapy facility in Hyderabad with a $75 million investment, expanding beyond its core vaccine business into advanced therapeutics. • The 50,000-square-foot facility will focus on developing treatments for oncology and rare diseases, with two cell therapies and three gene therapies currently in development and expected market launch by 2028. • The company aims to make these advanced therapies more cost-effective for the price-sensitive Indian market, targeting prices below 5 million rupees ($57,900) while also exploring export opportunities.